Recent Updates
Recently added Catalysts
VNRX Positive Sentiment

A novel immunoprecipitation/PCR method for detection of plasma cfDNA fragments selectively occupied by CTCF in cancer

Tuesday, February 6, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The poster presented at ESMO 2023 by D. Pamart et al. introduces a novel immunoprecipitation/PCR method aimed at detecting plasma cfDNA fragments that are selectively occupied by CTCF in cancer. This innovative approach could enhance the prognostic value of cancer tests, particularly the Nu.Q® Cancer Test.
Price reaction · baseline $23.8 (2024-02-06T16:57:00.000Z) · hit during market hours · 2 other VNRX headline(s) in the window, move may be shared
day 0 close · peak
-5.8%
day 1
0%
day 3
-5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Introduction of a novel method for cancer detection.
  • Potential for improved prognostic capabilities in cancer diagnostics.

Full Press Release Details

Poster titled “A novel immunoprecipitation/PCR method for detection of plasma cfDNA fragments selectively occupied by CTCF in cancer.”
Presented at ESMO 2023
D. Pamart et al

Related Articles

• Press Releases Data Showing the Prognostic Value of its Nu.Q® Cancer Test
• Poster & Publications Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

Data Showing the Prognostic Value of its Nu.Q® Cancer Test

Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

• Share
• Tweet
• Share on Facebook
• Share

Subscribe for Volition product updates .

Or, click here for Investor Updates and press releases .

" * " indicates required fields

Frequently Asked Questions

What is the focus of the presented poster?

The poster focuses on a novel immunoprecipitation/PCR method for detecting plasma cfDNA fragments in cancer.

Where was the poster presented?

The poster was presented at ESMO 2023.

Who are the authors of the study?

The study was authored by D. Pamart et al.

What is the significance of the new method?

The new method aims to improve the prognostic value of cancer tests.

ShareAdd on Google
Tags: VNRX Viatris Investor Conferences Healthcare cfDNA CTCF cancer ESMO 2023
Last updated: Feb 6, 2024

Biotech snapshot

Cash runway
$3M liquidity · $2M/mo burn
~1 mo
High dilution risk